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GENERAL COMMENTS
The paper is a clearly written account of a study that is highly relevant to the important issue highlighted in the opening paragraph of the need to attempt to avoid waste in research by commissioning work in areas of high clinical relevance. Broadly the paper's findings are interesting and credible, and provide useful data to inform the debates on this important issue.
There are, however, a few points that I believe might benefit from some revision, and the comments below explain why I answered 'no' to several of the questions on the review sheet: 1. Is the abstract accurate, balanced and complete?: I would advise the authors to provide slightly fuller details in the abstract about how the MORE system defines 'clinical relevance' and 'newsworthiness'. In particular, the latter could perhaps initially be misinterpreted by some readers as relating to media coverage, unless the brief definition is given at this stage.
Is the study design appropriate to answer the research question?
My reservation here relates to an assumption behind the second hypothesis. The authors hypothesise that reports published in Health Technology Assessment have a lower mean average MORE clinical relevance and newsworthiness rating than publications from the same research published elsewhere. The rationale for this is that 'prior publication may affect the relevance ratings of the report if study findings are already in the public domain.' I could not see, however, that the authors had attempted to produce evidence that would show how far publications from the same research published elsewhere were indeed published prior to the HTA report. I quickly skimmed the evidence from my previous study of the impact of the studies from the HTA Programme (Hanney et al, 2007) . While for pre-2007 publications this did suggest that quite often HTA-funded research was published elsewhere prior to publication in an HTA report, it also showed that this by no means happened every time. Perhaps the pattern has become more clear-cut since this earlier study, but I think this issue should be addressed. The ideal approach might have been separate subgroup analysis of those papers published elsewhere prior to the HTA report, and those published after the HTA report. It might be unrealistic to expect this to be done now, but perhaps the issue could at least be acknowledged in the discussion of the methods, and returned to in the limitations.
Are the discussion and conclusions justified by the results?
 I think the discussion of the results in relation to Hypothesis 2 should reflect the point I've made above.  While the discussion correctly focuses on the hypotheses, I wonder if the authors could also reflect more on the figures on Table 2 that show a much higher % of HTA-funded papers (both the HTA reports and the papers published elsewhere) passing CAP and MORE than non-HTA publications.  I believe the authors should look again at the first factor that it is claimed could explain the high clinical relevance of NIHR HTA reports. I agree that the fact that the HTA programme publishes its own journal does enable a high publication rate of funded studies, but I don't see why that should be thought to be a reason, per se, for a higher clinical relevance of HTA reports. Indeed, if anything, it might serve to depress the average score (as is implied by the authors' comment about the HTA journal not being affected by publication bias.) Would it not be more accurate to say the high clinical relevance rating is achieved despite, not because, the high publication rate of funded studies? I do agree that having its own journal enables longer accounts of findings and this might increase clinical relevance, as might the accessibility and structure of the reports.
Are the study limitations discussed adequately?
If my points about Hypothesis 2 cannot be fully addressed in the paper, perhaps they should be included in the limitations? 
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Reviewer One 1. Is the abstract accurate, balanced and complete?: I would advise the authors to provide slightly fuller details in the abstract about how the MORE system defines 'clinical relevance' and 'newsworthiness'.
Response: The abstract has been amended to provided these definitions. Again the abstract was subsequently edited to meet the abstract word limit.
2. Is the study design appropriate to answer the research question? My reservation here relates to an assumption behind the second hypothesis. The authors hypothesise that reports published in Health Technology Assessment have a lower mean average MORE clinical relevance and newsworthiness rating than publications from the same research published elsewhere. The rationale for this is that 'prior publication may affect the relevance ratings of the report if study findings are already in the public domain.' I could not see, however, that the authors had attempted to produce evidence that would show how far publications from the same research published elsewhere were indeed published prior to the HTA report. I quickly skimmed the evidence from my previous study of the impact of the studies from the HTA Programme (Hanney et al, 2007) . While for pre-2007 publications this did suggest that quite often HTA-funded research was published elsewhere prior to publication in an HTA report, it also showed that this by no means happened every time. Perhaps the pattern has become more clear-cut since this earlier study, but I think this issue should be addressed. The ideal approach might have been separate subgroup analysis of those papers published elsewhere prior to the HTA report, and those published after the HTA report. It might be unrealistic to expect this to be done now, but perhaps the issue could at least be acknowledged in the discussion of the methods, and returned to in the limitations.
Response: The paper has been amended in light of these helpful comments. The rationale for the second hypothesis in the Methods section has been extended to include a reference to Hanney's earlier work. Further research on time to publication of NIHR HTA funded reports has been completed subsequent to this study and, as Hanney suggests, has questioned the assumptions behind the second hypothesis. This is now included in the revised Discussion section. We acknowledge the desirability of subgroup analysis of prior and post report publications and have listed this both as a limitation and an area for further work in the Discussion section.
3. Are the discussion and conclusions justified by the results?
• I think the discussion of the results in relation to Hypothesis 2 should reflect the point I've made above.
Response: As stated previously, the Discussion has been revised.
• While the discussion correctly focuses on the hypotheses, I wonder if the authors could also reflect more on the figures on Table 2 that show a much higher % of HTA-funded papers (both the HTA reports and the papers published elsewhere) passing CAP and MORE than non-HTA publications.
Response: The Discussion has been revised to reflect on this finding.
• I believe the authors should look again at the first factor that it is claimed could explain the high clinical relevance of NIHR HTA reports. I agree that the fact that the HTA programme publishes its own journal does enable a high publication rate of funded studies, but I don't see why that should be thought to be a reason, per se, for a higher clinical relevance of HTA reports. Indeed, if anything, it might serve to depress the average score (as is implied by the authors' comment about the HTA journal not being affected by publication bias.) Would it not be more accurate to say the high clinical relevance rating is achieved despite, not because, the high publication rate of funded studies? I do agree that having its own journal enables longer accounts of findings and this might increase clinical relevance, as might the accessibility and structure of the reports.
Response: The Discussion section has been revised in response to this helpful comment.
4. Are the study limitations discussed adequately? If my points about Hypothesis 2 cannot be fully addressed in the paper, perhaps they should be included in the limitations?
Response: The limitations section of the Discussion has been revised.
I hope this provides sufficient response to the reviewer comments and look forward to hearing the outcome of this resubmission.
